PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate developments.
- “With important data readouts expected from our two lead programs, 2024 has the potential to be a transformational year for PepGen.
- People with myotonic dystrophy type 1 (DM1) currently have no approved treatment options that target the root cause of the disease.
- Financial Results for the Three Months and Twelve Months ended December 31, 2023
Cash and cash equivalents were $110.4 million as of December 31, 2023. - Net loss was $78.6 million for the year ended December 31, 2023, compared to $69.1 million for the same period in 2022.